Wen Feng Liu
Président chez CANICKEL MINING LIMITED
Relations actives
| Nom | Sexe | Age | Sociétés liées | Collaboration |
|---|---|---|---|---|
| Jian Guo Gao | M | - | 13 ans | |
| Shirley Anthony | F | - | 2 ans | |
| Lorne Waldman | M | 58 | 3 ans | |
| Xue Xin Zhu | M | 55 | 14 ans | |
| Yu Bai Zhang | M | - | 8 ans | |
| Weiliang Wang | M | - | 3 ans | |
| Ji Lang Li | M | - |
Hebei Wenfeng Industrial Group Co., Ltd.
 Hebei Wenfeng Industrial Group Co., Ltd. AluminumNon-Energy Minerals Hebei Wenfeng Industrial Group Co., Ltd. engages in the implementation of projects in the steel industry, equipment manufacturing, wood industry, biochemical new drug research and development, mining, and port construction. The company was founded on January 4, 2002 and is headquartered in Tangshan, China. | - |
| Feng Hai Shi | M | - |
Hebei Wenfeng Industrial Group Co., Ltd.
Hebei Wenfeng Industrial Group Co., Ltd. AluminumNon-Energy Minerals Hebei Wenfeng Industrial Group Co., Ltd. engages in the implementation of projects in the steel industry, equipment manufacturing, wood industry, biochemical new drug research and development, mining, and port construction. The company was founded on January 4, 2002 and is headquartered in Tangshan, China. | - |
| Ming Rong Lu | M | - |
Hebei Wenfeng Industrial Group Co., Ltd.
Hebei Wenfeng Industrial Group Co., Ltd. AluminumNon-Energy Minerals Hebei Wenfeng Industrial Group Co., Ltd. engages in the implementation of projects in the steel industry, equipment manufacturing, wood industry, biochemical new drug research and development, mining, and port construction. The company was founded on January 4, 2002 and is headquartered in Tangshan, China. | - |
| Shu Jin Yu | M | - |
Hebei Wenfeng Industrial Group Co., Ltd.
Hebei Wenfeng Industrial Group Co., Ltd. AluminumNon-Energy Minerals Hebei Wenfeng Industrial Group Co., Ltd. engages in the implementation of projects in the steel industry, equipment manufacturing, wood industry, biochemical new drug research and development, mining, and port construction. The company was founded on January 4, 2002 and is headquartered in Tangshan, China. | - |
| Jian Zhao Miao | M | - |
Hebei Wenfeng Industrial Group Co., Ltd.
Hebei Wenfeng Industrial Group Co., Ltd. AluminumNon-Energy Minerals Hebei Wenfeng Industrial Group Co., Ltd. engages in the implementation of projects in the steel industry, equipment manufacturing, wood industry, biochemical new drug research and development, mining, and port construction. The company was founded on January 4, 2002 and is headquartered in Tangshan, China. | - |
| Shu Hong Xiao | M | - |
Hebei Wenfeng Industrial Group Co., Ltd.
Hebei Wenfeng Industrial Group Co., Ltd. AluminumNon-Energy Minerals Hebei Wenfeng Industrial Group Co., Ltd. engages in the implementation of projects in the steel industry, equipment manufacturing, wood industry, biochemical new drug research and development, mining, and port construction. The company was founded on January 4, 2002 and is headquartered in Tangshan, China. | - |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
| Nom | Sexe | Age | Sociétés liées | Collaboration |
|---|---|---|---|---|
| James Dai | M | - | - | |
| Xiang Dong Tan | M | 69 |
Welichem Biotech, Inc.
 Welichem Biotech, Inc. Pharmaceuticals: MajorHealth Technology Welichem Biotech, Inc. operates as a drug discovery and early stage drug development company focusing on novel therapeutics for autoimmune, inflammatory diseases and cancers. The firm's focus has been on research and development of its novel anti-inflammatory drug candidate, WBI-1001 and its derivatives, and its anticancer drug candidate, WBI-2100 and its derivatives. The company was founded on November 1, 2004 and is headquartered in Burnaby, Canada. | 4 ans |
| Guoqing Li | M | - |
Welichem Biotech, Inc.
Welichem Biotech, Inc. Pharmaceuticals: MajorHealth Technology Welichem Biotech, Inc. operates as a drug discovery and early stage drug development company focusing on novel therapeutics for autoimmune, inflammatory diseases and cancers. The firm's focus has been on research and development of its novel anti-inflammatory drug candidate, WBI-1001 and its derivatives, and its anticancer drug candidate, WBI-2100 and its derivatives. The company was founded on November 1, 2004 and is headquartered in Burnaby, Canada. | 8 ans |
| Sandy Wang | F | - | 2 ans | |
| Raymond Humphrey | M | 72 | 3 ans | |
| Michael W. Hibbitts | M | - | 2 ans | |
| Ying Ting Guo | M | - | 6 ans | |
| John Pan | M | - | - | |
| Siu Cheong Lai | M | 73 | 3 ans | |
| Derek Liu | M | - | 5 ans | |
| Dianmin Chen | M | 66 | 1 ans | |
| Stan Bharti | M | 71 | 7 ans | |
| Brian Miller | M | - | - | |
| Rick Sproule | M | - | 2 ans | |
| Meilin Yi | M | - |
Welichem Biotech, Inc.
Welichem Biotech, Inc. Pharmaceuticals: MajorHealth Technology Welichem Biotech, Inc. operates as a drug discovery and early stage drug development company focusing on novel therapeutics for autoimmune, inflammatory diseases and cancers. The firm's focus has been on research and development of its novel anti-inflammatory drug candidate, WBI-1001 and its derivatives, and its anticancer drug candidate, WBI-2100 and its derivatives. The company was founded on November 1, 2004 and is headquartered in Burnaby, Canada. | - |
| Maurice John Colson | M | 79 | 6 ans | |
| Mark Trevisiol | M | 62 | 1 ans | |
| Mingrong Lu | F | - |
Welichem Biotech, Inc.
Welichem Biotech, Inc. Pharmaceuticals: MajorHealth Technology Welichem Biotech, Inc. operates as a drug discovery and early stage drug development company focusing on novel therapeutics for autoimmune, inflammatory diseases and cancers. The firm's focus has been on research and development of its novel anti-inflammatory drug candidate, WBI-1001 and its derivatives, and its anticancer drug candidate, WBI-2100 and its derivatives. The company was founded on November 1, 2004 and is headquartered in Burnaby, Canada. | - |
| Zhaofang Zhang | M | - |
Welichem Biotech, Inc.
Welichem Biotech, Inc. Pharmaceuticals: MajorHealth Technology Welichem Biotech, Inc. operates as a drug discovery and early stage drug development company focusing on novel therapeutics for autoimmune, inflammatory diseases and cancers. The firm's focus has been on research and development of its novel anti-inflammatory drug candidate, WBI-1001 and its derivatives, and its anticancer drug candidate, WBI-2100 and its derivatives. The company was founded on November 1, 2004 and is headquartered in Burnaby, Canada. | - |
| Patrick Gleeson | M | - | - | |
| Bernard Wilson | M | 80 | 4 ans | |
| York Yingping Guo | M | - |
Welichem Biotech, Inc.
Welichem Biotech, Inc. Pharmaceuticals: MajorHealth Technology Welichem Biotech, Inc. operates as a drug discovery and early stage drug development company focusing on novel therapeutics for autoimmune, inflammatory diseases and cancers. The firm's focus has been on research and development of its novel anti-inflammatory drug candidate, WBI-1001 and its derivatives, and its anticancer drug candidate, WBI-2100 and its derivatives. The company was founded on November 1, 2004 and is headquartered in Burnaby, Canada. | - |
| Weihe Wang | M | - |
Welichem Biotech, Inc.
Welichem Biotech, Inc. Pharmaceuticals: MajorHealth Technology Welichem Biotech, Inc. operates as a drug discovery and early stage drug development company focusing on novel therapeutics for autoimmune, inflammatory diseases and cancers. The firm's focus has been on research and development of its novel anti-inflammatory drug candidate, WBI-1001 and its derivatives, and its anticancer drug candidate, WBI-2100 and its derivatives. The company was founded on November 1, 2004 and is headquartered in Burnaby, Canada. | 1 ans |
| Yeyan Zhang | M | - |
Welichem Biotech, Inc.
Welichem Biotech, Inc. Pharmaceuticals: MajorHealth Technology Welichem Biotech, Inc. operates as a drug discovery and early stage drug development company focusing on novel therapeutics for autoimmune, inflammatory diseases and cancers. The firm's focus has been on research and development of its novel anti-inflammatory drug candidate, WBI-1001 and its derivatives, and its anticancer drug candidate, WBI-2100 and its derivatives. The company was founded on November 1, 2004 and is headquartered in Burnaby, Canada. | - |
| Hugh Wynne-Edwards | M | - |
Welichem Biotech, Inc.
Welichem Biotech, Inc. Pharmaceuticals: MajorHealth Technology Welichem Biotech, Inc. operates as a drug discovery and early stage drug development company focusing on novel therapeutics for autoimmune, inflammatory diseases and cancers. The firm's focus has been on research and development of its novel anti-inflammatory drug candidate, WBI-1001 and its derivatives, and its anticancer drug candidate, WBI-2100 and its derivatives. The company was founded on November 1, 2004 and is headquartered in Burnaby, Canada. | - |
| David Hunter | M | 57 | - |
Statistiques
| Pays | Relations | % du total |
|---|---|---|
| Canada | 32 | 84,21% |
| Chine | 6 | 15,79% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Wen Feng Liu
- Réseau Personnel
